Non-Alcoholic Fatty Liver Disease Latest Advances

Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.

Journal: Physiological research

Published: September 08, 2026

Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: September 07, 2026

Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: September 07, 2026

Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: September 07, 2026

NAFLD becomes MASLD, frequency and characteristics of non-obese metabolic dysfunction associated steatotic liver disease (MASLD) among patients seeking care at a tertiary medical facility.

Journal: JPMA. The Journal of the Pakistan Medical Association

Published: September 07, 2026

Exploration of the mechanisms of portal hypertension driven by metabolic disorders in non-cirrhotic stages of metabolic-associated fatty liver disease

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: September 07, 2026

Proportion and clinical characteristics of probable metabolic-associated fatty liver disease-related cirrhosis in cryptogenic cirrhosis

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: September 07, 2026

Research progress on the applicability of diagnostic criteria for metabolic and alcohol-related liver disease in patients with cirrhosis and after liver transplantation

Journal: Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology

Published: September 07, 2026

Associations of antihypertensive medication class with liver fibrosis and mortality in US adults with MASLD.

Journal: Clinical and experimental hypertension (New York, N.Y. : 1993)

Published: September 07, 2026

Integrated bioinformatics and SEM analysis reveal GPAM as a key mediator of fibrosis in NAFLD with metabolic dysfunction.

Journal: Journal of genetics

Published: September 04, 2026

Impact of bariatric surgery on cardiovascular and cerebrovascular outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide analysis.

Journal: Proceedings (Baylor University. Medical Center)

Published: September 04, 2026

Hepatic steatosis as a risk factor for postoperative delirium following hepatectomy: a retrospective cohort study.

Journal: Minerva anestesiologica

Published: September 04, 2026

Non-Alcoholic Fatty Liver Disease Latest Advances

Find the Latest Research About Non-Alcoholic Fatty Liver Disease

Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.

Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress.

Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease

Mesenchymal stem cell-derived exosomes: a new hope for metabolic-associated fatty liver disease

Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease

Considerations on clinical trial issues related to new drug development for metabolic and alcohol-associated liver disease and fatty liver disease

Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity

Across-sectional study on the association between steatotic liver disease and its subtypes, cardiovascular health status, and extrahepatic comorbidity

NAFLD becomes MASLD, frequency and characteristics of non-obese metabolic dysfunction associated steatotic liver disease (MASLD) among patients seeking care at a tertiary medical facility.

NAFLD becomes MASLD, frequency and characteristics of non-obese metabolic dysfunction associated steatotic liver disease (MASLD) among patients seeking care at a tertiary medical facility.

Exploration of the mechanisms of portal hypertension driven by metabolic disorders in non-cirrhotic stages of metabolic-associated fatty liver disease

Exploration of the mechanisms of portal hypertension driven by metabolic disorders in non-cirrhotic stages of metabolic-associated fatty liver disease

Proportion and clinical characteristics of probable metabolic-associated fatty liver disease-related cirrhosis in cryptogenic cirrhosis

Proportion and clinical characteristics of probable metabolic-associated fatty liver disease-related cirrhosis in cryptogenic cirrhosis

Research progress on the applicability of diagnostic criteria for metabolic and alcohol-related liver disease in patients with cirrhosis and after liver transplantation

Research progress on the applicability of diagnostic criteria for metabolic and alcohol-related liver disease in patients with cirrhosis and after liver transplantation

Associations of antihypertensive medication class with liver fibrosis and mortality in US adults with MASLD.

Associations of antihypertensive medication class with liver fibrosis and mortality in US adults with MASLD.

Integrated bioinformatics and SEM analysis reveal GPAM as a key mediator of fibrosis in NAFLD with metabolic dysfunction.

Integrated bioinformatics and SEM analysis reveal GPAM as a key mediator of fibrosis in NAFLD with metabolic dysfunction.

Impact of bariatric surgery on cardiovascular and cerebrovascular outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide analysis.

Impact of bariatric surgery on cardiovascular and cerebrovascular outcomes in metabolic dysfunction-associated steatotic liver disease: a nationwide analysis.

Hepatic steatosis as a risk factor for postoperative delirium following hepatectomy: a retrospective cohort study.

Hepatic steatosis as a risk factor for postoperative delirium following hepatectomy: a retrospective cohort study.